Physician profile
Alejandro Arizmendi
NPI 1457317232
$14,803.93
in general payments reported to CMS, 2019-2025
60 companies · $2,603 in 2025
The $2,603 reported for 2025 was more than what 96% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $2,138 · 2021: $2,091 · 2022: $2,295 · 2023: $2,090 · 2024: $2,095 · 2025: $2,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,787.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,124.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,892.82 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,411.84 | 2019-2025 | Repatha, Repatha, Krystexxa |
| Abbvie INC. | $1,117.38 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,098.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $701.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $524.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $469.21 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $428.85 | 2022-2025 | |
| Abbott Laboratories | $414.61 | 2020-2025 | Freestyle Libre 3, Proclaim |
| Janssen Pharmaceuticals, INC | $405.41 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $404.42 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.58 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $328.36 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $310.96 | 2019-2023 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Arizmendi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.